

The mechanism of acquired resistance to irreversible EGFR inhibitor-afatinib in lung adenocarcinoma patients

Oncotarget

7, 12404-12413

DOI: [10.18632/oncotarget.7189](https://doi.org/10.18632/oncotarget.7189)

Citation Report

#	ARTICLE	IF	CITATIONS
1	Heterogeneity of resistance mutations detectable by next-generation sequencing in TKI-treated lung adenocarcinoma. <i>Oncotarget</i> , 2016, 7, 45237-45248.	1.8	25
2	A potential new therapeutic option for patients with advanced EGFR mutation-positive non-small cell lung cancer in first-line setting. <i>Journal of Thoracic Disease</i> , 2016, 8, E1520-E1524.	1.4	0
3	Afatinib in lung cancer harboring EGFR mutation in the LUX-Lung trials: six plus three is greater than seven?. <i>Translational Lung Cancer Research</i> , 2016, 5, 446-449.	2.8	6
4	Resistance to Targeted Therapies Against Adult Brain Cancers. <i>Resistance To Targeted Anti-cancer Therapeutics</i> , 2016, , .	0.1	4
5	Update on recent preclinical and clinical studies of T790M mutant-specific irreversible epidermal growth factor receptor tyrosine kinase inhibitors. <i>Journal of Biomedical Science</i> , 2016, 23, 86.	7.0	41
6	Assessment of the clinical application of detecting EGFR, KRAS, PIK3CA and BRAF mutations in patients with non-small cell lung cancer using next-generation sequencing. <i>Scandinavian Journal of Clinical and Laboratory Investigation</i> , 2016, 76, 386-392.	1.2	13
7	LUX-Lung 7: is there enough data for a final conclusion?. <i>Lancet Oncology</i> , The, 2016, 17, e266-e267.	10.7	0
8	Acquired Resistance to First-Line Afatinib and the Challenges of Prearranged Progression Biopsies. <i>Journal of Thoracic Oncology</i> , 2016, 11, 2022-2026.	1.1	73
9	LUX-Lung 7: is there enough data for a final conclusion? – Author's reply. <i>Lancet Oncology</i> , The, 2016, 17, e268-e269.	10.7	0
10	Afatinib: A Review in Advanced Non-Small Cell Lung Cancer. <i>Targeted Oncology</i> , 2016, 11, 825-835.	3.6	33
11	Osimertinib for pretreated EGFR Thr790Met-positive advanced non-small-cell lung cancer (AURA2): a multicentre, open-label, single-arm, phase 2 study. <i>Lancet Oncology</i> , The, 2016, 17, 1643-1652.	10.7	533
12	Novel EGFR Inhibitors in Non-small Cell Lung Cancer: Current Status of Afatinib. <i>Current Oncology Reports</i> , 2017, 19, 4.	4.0	15
13	Most T790M mutations are present on the same EGFR allele as activating mutations in patients with non-small cell lung cancer. <i>Lung Cancer</i> , 2017, 108, 75-82.	2.0	37
14	Characterization of EGFR T790M, L792F, and C797S Mutations as Mechanisms of Acquired Resistance to Afatinib in Lung Cancer. <i>Molecular Cancer Therapeutics</i> , 2017, 16, 357-364.	4.1	65
15	Optimal management of EGFR -mutant non-small cell lung cancer with disease progression on first-line tyrosine kinase inhibitor therapy. <i>Lung Cancer</i> , 2017, 110, 7-13.	2.0	40
16	EGFR Mutation Analysis for Prospective Patient Selection in Two Phase II Registration Studies of Osimertinib. <i>Journal of Thoracic Oncology</i> , 2017, 12, 1247-1256.	1.1	48
17	Comparison of the effectiveness of erlotinib, gefitinib, and afatinib for treatment of non-small cell lung cancer in patients with common and rare EGFR gene mutations. <i>Oncology Letters</i> , 2017, 13, 4433-4444.	1.8	53
18	Osimertinib in patients with advanced epidermal growth factor receptor T790M mutation-positive non-small cell lung cancer: rationale, evidence and place in therapy. <i>Therapeutic Advances in Medical Oncology</i> , 2017, 9, 387-404.	3.2	30

#	ARTICLE	IF	CITATIONS
19	Treatment choice in epidermal growth factor receptor mutation-positive non-small cell lung carcinoma: latest evidence and clinical implications. <i>Therapeutic Advances in Medical Oncology</i> , 2017, 9, 201-216.	3.2	30
20	Distinct Afatinib Resistance Mechanisms Identified in Lung Adenocarcinoma Harboring an EGFR Mutation. <i>Molecular Cancer Research</i> , 2017, 15, 915-928.	3.4	37
21	Targeting the EGFR T790M mutation in non-small-cell lung cancer. <i>Expert Opinion on Therapeutic Targets</i> , 2017, 21, 159-165.	3.4	28
22	Continued use of afatinib with the addition of cetuximab after progression on afatinib in patients with EGFR mutation-positive non-small-cell lung cancer and acquired resistance to gefitinib or erlotinib. <i>Lung Cancer</i> , 2017, 113, 51-58.	2.0	16
23	Third generation EGFR TKIs in EGFR-mutated NSCLC: Where are we now and where are we going. <i>Critical Reviews in Oncology/Hematology</i> , 2017, 117, 38-47.	4.4	85
24	Resistance to epithelial growth factor receptor tyrosine kinase inhibitors in a patient with transformation from lung adenocarcinoma to small cell lung cancer: A case report. <i>Oncology Letters</i> , 2017, 14, 593-598.	1.8	11
25	Afatinib versus gefitinib in patients with EGFR mutation-positive advanced non-small-cell lung cancer: overall survival data from the phase IIb LUX-Lung 7 trial. <i>Annals of Oncology</i> , 2017, 28, 270-277.	1.2	425
26	Overcoming On-Target Resistance to Tyrosine Kinase Inhibitors in Lung Cancer. <i>Annual Review of Cancer Biology</i> , 2017, 1, 257-274.	4.5	4
27	Clinical Pharmacokinetics and Pharmacodynamics of Afatinib. <i>Clinical Pharmacokinetics</i> , 2017, 56, 235-250.	3.5	138
28	Osimertinib for EGFR T790M mutation-positive non-small cell lung cancer. <i>Expert Review of Clinical Pharmacology</i> , 2017, 10, 31-38.	3.1	23
29	Squamous cell transformation and EGFR T790M mutation as acquired resistance mechanisms in a patient with lung adenocarcinoma treated with a tyrosine kinase inhibitor: A case report. <i>Oncology Letters</i> , 2017, 14, 5947-5951.	1.8	16
30	Real-world experience of afatinib as a first-line therapy for advanced EGFR mutation-positive lung adenocarcinoma. <i>Oncotarget</i> , 2017, 8, 90430-90443.	1.8	63
31	Cross-Platform Comparison of Four Leading Technologies for Detecting EGFR Mutations in Circulating Tumor DNA from Non-Small Cell Lung Carcinoma Patient Plasma. <i>Theranostics</i> , 2017, 7, 1437-1446.	10.0	75
32	Management of Egfr-Mutated Non-Small-Cell Lung Cancer: Practical Implications from a Clinical and Pathology Perspective. <i>Current Oncology</i> , 2017, 24, 111-119.	2.2	19
33	The efficacy of 40 mg versus dose de-escalation to less than 40 mg of afatinib (Giotrif) as the first-line therapy for patients with primary lung adenocarcinoma harboring favorable epidermal growth factor mutations. <i>Oncotarget</i> , 2017, 8, 97602-97612.	1.8	25
34	Adenocarcinoma of the Lung Acquiring Resistance to Afatinib by Transformation to Small Cell Carcinoma: A Case Report. <i>Case Reports in Oncology</i> , 2017, 10, 666-670.	0.7	3
35	Activation of signal transducer and activator of transcription 3 (STAT3) signaling in EGFR mutant non-small-cell lung cancer (NSCLC). <i>Oncotarget</i> , 2017, 8, 47305-47316.	1.8	40
36	Mechanisms of resistance to irreversible epidermal growth factor receptor tyrosine kinase inhibitors and therapeutic strategies in non-small cell lung cancer. <i>Oncotarget</i> , 2017, 8, 90557-90578.	1.8	34

#	ARTICLE	IF	CITATIONS
37	Acquisition of the T790M resistance mutation during afatinib treatment in EGFR tyrosine kinase inhibitor-naïve patients with non-small cell lung cancer harboring EGFR mutations. <i>Oncotarget</i> , 2017, 8, 68123-68130.	1.8	63
38	Case sharing of a patient re-challenged with afatinib for EGFR-mutated advanced non-small cell lung cancer. <i>Asia-Pacific Journal of Clinical Oncology</i> , 2018, 14, 4-6.	1.1	2
39	Management of acquired resistance to EGFR TKI-targeted therapy in advanced non-small cell lung cancer. <i>Molecular Cancer</i> , 2018, 17, 38.	19.2	489
40	Identification of Novel Pathways of Osimertinib Disposition and Potential Implications for the Outcome of Lung Cancer Therapy. <i>Clinical Cancer Research</i> , 2018, 24, 2138-2147.	7.0	21
41	Molecular Testing for Stage IV Non-Small Cell Lung Cancer Patients With Targetable Mutations Following Disease Progression. <i>Archives of Pathology and Laboratory Medicine</i> , 2018, 142, 799-800.	2.5	0
42	Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors for Central Nervous System Metastases from Non-Small Cell Lung Cancer. <i>Oncologist</i> , 2018, 23, 1199-1209.	3.7	42
43	Turning EGFR mutation-positive non-small-cell lung cancer into a chronic disease: optimal sequential therapy with EGFR tyrosine kinase inhibitors. <i>Therapeutic Advances in Medical Oncology</i> , 2018, 10, 175883401775333.	3.2	41
44	Global named patient use program of afatinib in advanced non-small-cell lung carcinoma patients who progressed following prior therapies. <i>Future Oncology</i> , 2018, 14, 1477-1486.	2.4	14
45	EGFR-mediated interleukin enhancer-binding factor 3 contributes to formation and survival of cancer stem-like tumorspheres as a therapeutic target against EGFR-positive non-small cell lung cancer. <i>Lung Cancer</i> , 2018, 116, 80-89.	2.0	23
46	Using Genome Sequence to Enable the Design of Medicines and Chemical Probes. <i>Chemical Reviews</i> , 2018, 118, 1599-1663.	47.7	64
47	Effects of trastuzumab and afatinib on kinase activity in gastric cancer cell lines. <i>Molecular Oncology</i> , 2018, 12, 441-462.	4.6	15
48	FLNa negatively regulated proliferation and metastasis in lung adenocarcinoma A549 cells via suppression of EGFR. <i>Acta Biochimica Et Biophysica Sinica</i> , 2018, 50, 164-170.	2.0	31
49	First-line therapy for advanced non-small cell lung cancer with activating EGFR mutation: is combined EGFR-TKIs and chemotherapy a better choice?. <i>Cancer Chemotherapy and Pharmacology</i> , 2018, 81, 443-453.	2.3	10
50	Transformation to small cell lung cancer after first-line afatinib treatment. <i>Respiratory Medicine Case Reports</i> , 2018, 23, 188-190.	0.4	8
51	Afatinib in advanced NSCLC: a profile of its use. <i>Drugs and Therapy Perspectives</i> , 2018, 34, 89-98.	0.6	14
52	Outcomes of research biopsies in clinical trials of EGFR mutation-positive non-small cell lung cancer patients pretreated with EGFR-tyrosine kinase inhibitors. <i>Journal of the Formosan Medical Association</i> , 2018, 117, 326-331.	1.7	10
53	Phase I study of the combination of quinacrine and erlotinib in patients with locally advanced or metastatic non small cell lung cancer. <i>Investigational New Drugs</i> , 2018, 36, 435-441.	2.6	15
54	New Targets for Therapy in Lung Cancer. , 2018, , 479-489.e6.		1

#	ARTICLE	IF	CITATIONS
55	Update on EGFR Mutational Testing and the Potential of Noninvasive Liquid Biopsy in Non-Small-cell Lung Cancer. <i>Clinical Lung Cancer</i> , 2018, 19, 105-114.	2.6	22
56	Lung cancer in never smokers—the East Asian experience. <i>Translational Lung Cancer Research</i> , 2018, 7, 450-463.	2.8	104
57	Mechanism of Resistance to Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitors and a Potential Treatment Strategy. <i>Cells</i> , 2018, 7, 212.	4.1	190
58	Mechanisms of acquired resistance to afatinib clarified with liquid biopsy. <i>PLoS ONE</i> , 2018, 13, e0209384.	2.5	25
59	The impact of the tumor shrinkage by initial EGFR inhibitors according to the detection of EGFR-T790M mutation in patients with non-small cell lung cancer harboring EGFR mutations. <i>BMC Cancer</i> , 2018, 18, 1241.	2.6	1
60	Glycoproteomic Alterations in Drug-Resistant Nonsmall Cell Lung Cancer Cells Revealed by Lectin Magnetic Nanoprobe-Based Mass Spectrometry. <i>Journal of Proteome Research</i> , 2018, 17, 3761-3773.	3.7	26
61	Effects of secondary EGFR mutations on resistance against upfront osimertinib in cells with EGFR-activating mutations in vitro. <i>Lung Cancer</i> , 2018, 126, 149-155.	2.0	40
62	An observational study of the epidermal growth factor receptor-tyrosine kinase inhibitor resistance mechanism in epidermal growth factor receptor gene mutation-positive non-small cell lung cancer. <i>Medicine (United States)</i> , 2018, 97, e12660.	1.0	0
63	Sequential treatment with afatinib and osimertinib in patients with EGFR mutation-positive non-small-cell lung cancer: an observational study. <i>Future Oncology</i> , 2018, 14, 2861-2874.	2.4	90
64	The roles of tumor-derived exosomes in non-small cell lung cancer and their clinical implications. <i>Journal of Experimental and Clinical Cancer Research</i> , 2018, 37, 226.	8.6	107
65	A Study of Diagnostic Accuracy Using a Chemical Sensor Array and a Machine Learning Technique to Detect Lung Cancer. <i>Sensors</i> , 2018, 18, 2845.	3.8	52
66	Effect of multiple-dose osimertinib on the pharmacokinetics of simvastatin and rosuvastatin. <i>British Journal of Clinical Pharmacology</i> , 2018, 84, 2877-2888.	2.4	20
67	Consensus on Molecular Testing in Lung Cancer. <i>Current Pulmonology Reports</i> , 2018, 7, 49-55.	1.3	2
68	Acquired resistance in oncogene-addicted non-small-cell lung cancer. <i>Future Oncology</i> , 2018, 14, 29-40.	2.4	18
69	Phase Ib Study of High-dose Intermittent Afatinib in Patients With Advanced Solid Tumors. <i>Clinical Lung Cancer</i> , 2018, 19, e655-e665.	2.6	7
70	YES1 amplification is a mechanism of acquired resistance to EGFR inhibitors identified by transposon mutagenesis and clinical genomics. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2018, 115, E6030-E6038.	7.1	44
71	Primary Cilia Mediate Diverse Kinase Inhibitor Resistance Mechanisms in Cancer. <i>Cell Reports</i> , 2018, 23, 3042-3055.	6.4	77
72	Prior EGFR-TKI Treatment in EGFR-Mutated NSCLC Affects the Allele Frequency Fraction of Acquired T790M and the Subsequent Efficacy of Osimertinib. <i>Targeted Oncology</i> , 2019, 14, 433-440.	3.6	9

#	ARTICLE	IF	CITATIONS
73	Receptor Tyrosine Kinase Fusions as an Actionable Resistance Mechanism to EGFR TKIs in EGFR-Mutant Non-Small-Cell Lung Cancer. Trends in Cancer, 2019, 5, 677-692.	7.4	43
74	Optimizing outcomes and treatment sequences in <i>EGFR</i> mutation-positive non-small-cell lung cancer: recent updates. Future Oncology, 2019, 15, 2983-2997.	2.4	27
75	<p><p>Second-generation EGFR and ErbB tyrosine kinase inhibitors as first-line treatments for non-small cell lung cancer</p></p>. OncoTargets and Therapy, 2019, Volume 12, 6535-6548.	2.0	26
76	Real-world experience of first-line afatinib in patients with EGFR-mutant advanced NSCLC: a multicenter observational study. BMC Cancer, 2019, 19, 896.	2.6	33
77	Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors in non-small cell lung cancer harboring uncommon EGFR mutations: Focus on afatinib. Seminars in Oncology, 2019, 46, 271-283.	2.2	61
78	Approved and Clinical Trial Third-Generation EGFR Inhibitors. , 2019, , 25-43.		3
79	Role of osimertinib in the treatment of EGFR-mutation positive non-small-cell lung cancer. Future Oncology, 2019, 15, 805-816.	2.4	32
80	Immune checkpoint inhibitor treatment in patients with oncogene-addicted non-small cell lung cancer (NSCLC): summary of a multidisciplinary round-table discussion. ESMO Open, 2019, 4, e000498.	4.5	38
81	Afatinib is effective in the treatment of lung adenocarcinoma with uncommon EGFR p.L747P and p.L747S mutations. Lung Cancer, 2019, 133, 103-109.	2.0	29
82	Osimertinib (TAGRISSO®,) and the cobas® EGFR Mutation Test v2. , 2019, , 429-443.		2
83	The Ticking clock of EGFR therapy resistance in glioblastoma: Target Independence or target Compensation. Drug Resistance Updates, 2019, 43, 29-37.	14.4	33
84	Comparison of T790M Acquisition Between Patients Treated with Afatinib and Gefitinib as First-Line Therapy: Retrospective Propensity Score Matching Analysis. Translational Oncology, 2019, 12, 852-858.	3.7	14
85	First-line afatinib for the treatment of <i>EGFR</i> mutation-positive non-small-cell lung cancer in the “real-world” clinical setting. Therapeutic Advances in Medical Oncology, 2019, 11, 175883591983637.	3.2	25
86	Clinical Characteristics of Osimertinib Responder in Non-Small Cell Lung Cancer Patients with EGFR-T790M Mutation. Cancers, 2019, 11, 365.	3.7	8
87	Duration of treatment among patients prescribed afatinib or erlotinib as first-line therapy for EGFR mutation-positive non-small-cell lung cancer in the USA. Future Oncology, 2019, 15, 1493-1504.	2.4	6
88	Pulmonary Adenocarcinoma”Pathology and Molecular Testing. , 2019, , 13-33.		1
89	Epidermal growth factor receptor tyrosine kinase inhibitors for the treatment of non-small cell lung cancer. Expert Review of Anticancer Therapy, 2019, 19, 547-559.	2.4	22
90	Rationale for Using Irreversible Epidermal Growth Factor Receptor Inhibitors in Combination with Phosphatidylinositol 3-Kinase Inhibitors for Advanced Head and Neck Squamous Cell Carcinoma. Molecular Pharmacology, 2019, 95, 528-536.	2.3	17

#	ARTICLE	IF	CITATION
91	Expression of LDH and CEA in serum in the process of targeted therapy of lung adenocarcinoma and the association between them and prognosis. <i>Oncology Letters</i> , 2019, 17, 4550-4556.	1.8	7
92	Retrospective efficacy analysis of immune checkpoint inhibitors in patients with EGFR-mutated non-small cell lung cancer. <i>Cancer Medicine</i> , 2019, 8, 1521-1529.	2.8	82
93	Repeat biopsy procedures and T790M rates after afatinib, gefitinib, or erlotinib therapy in patients with lung cancer. <i>Lung Cancer</i> , 2019, 130, 87-92.	2.0	39
94	Increase of secondary mutations may be a drug-resistance mechanism for lung adenocarcinoma after radiation therapy combined with tyrosine kinase inhibitor. <i>Journal of Cancer</i> , 2019, 10, 5371-5376.	2.5	3
95	Second-line treatment of EGFR T790M-negative non-small cell lung cancer patients. <i>Therapeutic Advances in Medical Oncology</i> , 2019, 11, 175883591989028.	3.2	28
96	SMAD4 Mutation in Small Cell Transformation of Epidermal Growth Factor Receptor Mutated Lung Adenocarcinoma. <i>Oncologist</i> , 2019, 24, 9-13.	3.7	10
97	Tumor clonality and resistance mechanisms in EGFR mutation-positive non-small-cell lung cancer: implications for therapeutic sequencing. <i>Future Oncology</i> , 2019, 15, 637-652.	2.4	80
98	First- and Second-Generation EGFR-TKIs Are All Replaced to Osimertinib in Chemo-Naïve EGFR Mutation-Positive Non-Small Cell Lung Cancer?. <i>International Journal of Molecular Sciences</i> , 2019, 20, 146.	4.1	118
99	AXL confers intrinsic resistance to osimertinib and advances the emergence of tolerant cells. <i>Nature Communications</i> , 2019, 10, 259.	12.8	223
100	Liquid-Biopsy-Based Identification of EGFR T790M Mutation-Mediated Resistance to Afatinib Treatment in Patients with Advanced EGFR Mutation-Positive NSCLC, and Subsequent Response to Osimertinib. <i>Targeted Oncology</i> , 2019, 14, 75-83.	3.6	102
101	Clinical outcomes and secondary epidermal growth factor receptor (EGFR) T790M mutation among first-line gefitinib, erlotinib and afatinib-treated non-small cell lung cancer patients with activating EGFR mutations. <i>International Journal of Cancer</i> , 2019, 144, 2887-2896.	5.1	56
102	Absolute Bioavailability of Osimertinib in Healthy Adults. <i>Clinical Pharmacology in Drug Development</i> , 2019, 8, 198-207.	1.6	22
103	Incidence of T790M in Patients With NSCLC Progressed to Gefitinib, Erlotinib, and Afatinib: A Study on Circulating Cell-free DNA. <i>Clinical Lung Cancer</i> , 2020, 21, 232-237.	2.6	24
104	Therapies after first-line afatinib in patients with EGFR ^m NSCLC in Japan: retrospective analysis of LUX-Lung 3. <i>Future Oncology</i> , 2020, 16, 49-60.	2.4	4
105	Tyrosine Kinase Inhibitors for the Treatment of EGFR Mutation-Positive Non-Small-Cell Lung Cancer: A Clash of the Generations. <i>Clinical Lung Cancer</i> , 2020, 21, e216-e228.	2.6	89
106	Afatinib for the first-line treatment of EGFR mutation-positive NSCLC in China: a review of clinical data. <i>Future Oncology</i> , 2020, 16, 2569-2586.	2.4	2
107	<p>>LncRNA LINC01116 Contributes to Cisplatin Resistance in Lung Adenocarcinoma</p><p>>. </p><p>>OncoTargets and Therapy, 2020, Volume 13, 9333-9347.	2.0	24
108	The Role of the Liquid Biopsy in Decision-Making for Patients with Non-Small Cell Lung Cancer. <i>Journal of Clinical Medicine</i> , 2020, 9, 3674.	2.4	8

#	ARTICLE	IF	CITATIONS
109	High expression of NEK2 promotes lung cancer progression and drug resistance and is regulated by mutant EGFR. <i>Molecular and Cellular Biochemistry</i> , 2020, 475, 15-25.	3.1	15
110	Making the case for EGFR TKI sequencing in <i>EGFR</i> mutation-positive NSCLC: a GioTag study US patient analysis. <i>Future Oncology</i> , 2020, 16, 1585-1595.	2.4	5
111	The effectiveness of afatinib in patients with lung adenocarcinoma harboring complex epidermal growth factor receptor mutation. <i>Therapeutic Advances in Medical Oncology</i> , 2020, 12, 175883592094615.	3.2	15
112	An Observational Study of Acquired EGFR T790M-Dependent Resistance to EGFR-TKI Treatment in Lung Adenocarcinoma Patients in Taiwan. <i>Frontiers in Oncology</i> , 2020, 10, 1481.	2.8	25
113	Switching from first or second generation EGFR-TKI to osimertinib in EGFR mutation-positive NSCLC. <i>Lung Cancer Management</i> , 2020, 9, LMT29.	1.5	5
114	Mutational spectrum of acquired resistance to reversible versus irreversible EGFR tyrosine kinase inhibitors. <i>BMC Cancer</i> , 2020, 20, 408.	2.6	14
115	Canadian Consensus: A New Systemic Treatment Algorithm for Advanced EGFR-Mutated Non-Small-Cell Lung Cancer. <i>Current Oncology</i> , 2020, 27, 146-155.	2.2	14
116	Clinical Factors Affecting the Response to Osimertinib in Non-Small Cell Lung Cancer Patients with An Acquired Epidermal Growth Factor Receptor T790M Mutation: A Long-Term Survival Analysis. <i>Targeted Oncology</i> , 2020, 15, 337-345.	3.6	4
117	Afatinib for the treatment of <i>EGFR</i> mutation-positive NSCLC: A review of clinical findings. <i>Journal of Oncology Pharmacy Practice</i> , 2020, 26, 1461-1474.	0.9	61
118	Advances in targeting acquired resistance mechanisms to epidermal growth factor receptor tyrosine kinase inhibitors. <i>Journal of Thoracic Disease</i> , 2020, 12, 2859-2876.	1.4	11
119	Routine-Dose and High-Dose Icotinib in Patients with Advanced Nonâ€‘Small Cell Lung Cancer Harboring EGFR Exon 21-L858R Mutation: the Randomized, Phase II, INCREASE Trial. <i>Clinical Cancer Research</i> , 2020, 26, 3162-3171.	7.0	16
120	Risk factors of acquired T790M mutation in patients with epidermal growth factor receptor-mutated advanced non-small cell lung cancer. <i>Journal of Cancer</i> , 2020, 11, 2060-2067.	2.5	7
121	Four generations of EGFR TKIs associated with different pathogenic mutations in non-small cell lung carcinoma. <i>Journal of Drug Targeting</i> , 2020, 28, 861-872.	4.4	11
122	Front-line Therapy in Advanced Nonâ€‘Small Cell Lung Cancer With Sensitive Epidermal Growth Factor Receptor Mutations: A Network Meta-analysis. <i>Clinical Therapeutics</i> , 2020, 42, 338-350.e4.	2.5	13
123	Secondary Resistant Mutations to Small Molecule Inhibitors in Cancer Cells. <i>Cancers</i> , 2020, 12, 927.	3.7	6
124	Identification of microRNAs that promote erlotinib resistance in non-small cell lung cancer. <i>Biochemical Pharmacology</i> , 2021, 189, 114154.	4.4	17
125	Celastrol acts synergistically with afatinib to suppress nonâ€‘small cell lung cancer cell proliferation by inducing paraptosis. <i>Journal of Cellular Physiology</i> , 2021, 236, 4538-4554.	4.1	21
126	Optimizing therapy sequence to prevent patient attrition in EGFR mutation-positive advanced or metastatic NSCLC. <i>Future Oncology</i> , 2021, 17, 471-486.	2.4	11

#	ARTICLE	IF	CITATIONS
127	Research Progress of Acquired EGFR-TKI Resistance in Patients with Advanced Lung Adenocarcinoma. <i>Advances in Clinical Medicine</i> , 2021, 11, 3949-3958.	0.0	0
128	The Impact of Acquired EGFR T790M Mutation and EGFR Circulating Cell-Free DNA on Survival in Patients with Lung Adenocarcinoma Following EGFR-TKI Therapy. <i>OncoTargets and Therapy</i> , 2020, Volume 13, 13425-13435.	2.0	5
129	Development and Challenges of the Discovery of HER2 Inhibitors. <i>Mini-Reviews in Medicinal Chemistry</i> , 2021, 20, 2123-2134.	2.4	2
130	The efficacy and safety of Osimertinib in advanced non-small cell lung cancer patients with Thr790Met resistance mutations: a systematic review and meta-analysis. <i>Annals of Palliative Medicine</i> , 2021, 10, 1851-1860.	1.2	1
131	Afatinib as First-Line Treatment in Asian Patients with EGFR Mutation-Positive NSCLC: A Narrative Review of Real-World Evidence. <i>Advances in Therapy</i> , 2021, 38, 2038-2053.	2.9	8
132	Clinical impact of subclonal EGFR T790M mutations in advanced-stage EGFR-mutant non-small-cell lung cancers. <i>Nature Communications</i> , 2021, 12, 1780.	12.8	39
133	A Real-World, Observational, Prospective Study to Assess the Molecular Epidemiology of Epidermal Growth Factor Receptor (EGFR) Mutations upon Progression on or after First-Line Therapy with a First- or Second-Generation EGFR Tyrosine Kinase Inhibitor in EGFR Mutation-Positive Locally Advanced or Metastatic Non-Small Cell Lung Cancer: The "LUNGFUL" Study. <i>Cancers</i> , 2021, 13, 3172.	3.7	6
134	An open-label expanded access program of afatinib in EGFR tyrosine kinase inhibitor-naïve patients with locally advanced or metastatic non-small cell lung cancer harboring EGFR mutations. <i>BMC Cancer</i> , 2021, 21, 802.	2.6	5
135	The role of molecular heterogeneity targeting resistance mechanisms to lung cancer therapies. <i>Expert Review of Molecular Diagnostics</i> , 2021, 21, 757-766.	3.1	4
136	An Observational Study to Assess the Molecular Epidemiology and Direct Medical Costs of Epidermal Growth Factor Receptor (EGFR) Mutations in Patients with Advanced EGFR Mutation-Positive Non-Small Cell Lung Cancer Treated with Afatinib in Real-World Clinical Settings in Greece. <i>Lung Cancer: Targets and Therapy</i> , 2021, Volume 12, 93-102.	2.7	1
137	Outcomes of salvage lung resections in advanced EGFR-mutant lung adenocarcinomas under EGFR TKIs. <i>Thoracic Cancer</i> , 2021, 12, 2655-2665.	1.9	10
138	Treatment Options of First-Line Tyrosine Kinase Inhibitors and Subsequent Systemic Chemotherapy Agents for Advanced EGFR Mutant Lung Adenocarcinoma Patients: Implications From Taiwan Cancer Registry Cohort. <i>Frontiers in Oncology</i> , 2020, 10, 590356.	2.8	4
139	Serial Plasma Cell-Free Circulating Tumor DNA Tests Identify Genomic Alterations for Early Prediction of Osimertinib Treatment Outcome in EGFR T790M-Positive NSCLC. <i>JTO Clinical and Research Reports</i> , 2021, 2, 100099.	1.1	0
141	YM155 as an inhibitor of cancer stemness simultaneously inhibits autophosphorylation of epidermal growth factor receptor and G9a-mediated stemness in lung cancer cells. <i>PLoS ONE</i> , 2017, 12, e0182149.	2.5	28
142	Overall survival in EGFR mutated non-small-cell lung cancer patients treated with afatinib after EGFR TKI and resistant mechanisms upon disease progression. <i>PLoS ONE</i> , 2017, 12, e0182885.	2.5	21
143	MTOR inhibition reversed drug resistance after combination radiation with erlotinib in lung adenocarcinoma. <i>Oncotarget</i> , 2016, 7, 84688-84694.	1.8	12
144	Change from lung adenocarcinoma to small cell lung cancer as a mechanism of resistance to afatinib. <i>Oncotarget</i> , 2017, 8, 59986-59990.	1.8	11
145	The activation of SRC family kinases and focal adhesion kinase with the loss of the amplified, mutated EGFR gene contributes to the resistance to afatinib, erlotinib and osimertinib in human lung cancer cells. <i>Oncotarget</i> , 2017, 8, 70736-70751.	1.8	26

#	ARTICLE	IF	CITATIONS
146	Antibody-assisted target identification reveals afatinib, an EGFR covalent inhibitor, down-regulating ribonucleotide reductase. <i>Oncotarget</i> , 2018, 9, 21512-21529.	1.8	10
147	Does afatinib plus bevacizumab combination therapy induce positive conversion of T790M in previously-negative patients?. <i>Oncotarget</i> , 2018, 9, 34765-34771.	1.8	7
148	Epidermal growth factor receptor-mutated non-small-cell lung cancer: A primer on contemporary management. <i>Cancer Research Statistics and Treatment</i> , 2019, 2, 36.	0.6	23
149	The Association of Acquired T790M Mutation with Clinical Characteristics after Resistance to First-Line Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor in Lung Adenocarcinoma. <i>Cancer Research and Treatment</i> , 2018, 50, 1294-1303.	3.0	49
150	Comparing survival and treatment response of patients with acquired <scp>T790M</scp> mutation secondâ€line osimertinib versus sequential treatment of chemotherapy followed by osimertinib: A realâ€world study. <i>Thoracic Cancer</i> , 2021, 12, 3263-3272.	1.9	2
151	Resistance of Brain Tumours to Small-Molecule-Targeted Therapies: Lessons from Various Cancer Types. <i>Resistance To Targeted Anti-cancer Therapeutics</i> , 2016, , 89-105.	0.1	0
153	AFATINIB IN THE TREATMENT OF METASTATIC AND LOCALLY ADVANCED LUNG ADENOCARCINOMA WITH EGFR MUTATIONS: NEW SIDES STUDIED POSSIBILITIES. <i>Meditinskiy Sovet</i> , 2017, , 46-55.	0.5	0
154	The evolution of views on the possibilities of drug therapy in overcoming acquired resistance not associated with T790M mutation to anti-EGFR drugs in non-small cell lung cancer. <i>Journal of Modern Oncology</i> , 2018, 20, 10-18.	0.3	0
155	Involvement of SNX1 in regulating EGFR endocytosis in a gefitinib-resistant NSCLC cell lines. <i>Cancer Drug Resistance (Alhambra, Calif)</i> , 2019, 2, 539-549.	2.1	0
156	The biology of Epidermal Growth Factor Receptor (EGFR) from regulating cell cycle to promoting carcinogenesis: the state of art including treatment options. <i>Annals of Cytology and Pathology</i> , 2020, 5, 048-053.	0.4	3
157	Critical Review of EGFR-Mutated NSCLC: What We Do and Do Not Know. <i>Healthbook TIMES Oncology Hematology</i> , 2020, , 20-35.	0.1	3
158	Molecular dynamics, MM/PBSA and inÂvitro validation of a novel quinazoline-based EGFR tyrosine kinase inhibitor identified using structure-based in silico screening. <i>Journal of Molecular Graphics and Modelling</i> , 2020, 99, 107639.	2.4	6
160	NOTCH alteration in EGFR-mutated lung adenocarcinoma leads to histological small-cell carcinoma transformation under EGFR-TKI treatment. <i>Translational Lung Cancer Research</i> , 2021, 10, 4161-4173.	2.8	5
161	Treatment patterns, testing practices, and outcomes in the pre-FLAURA era for patients with EGFR mutation-positive advanced NSCLC: a retrospective chart review (REFLECT). <i>Therapeutic Advances in Medical Oncology</i> , 2021, 13, 175883592110598.	3.2	6
162	Discovery of potent antiproliferative agents from selected oxygen heterocycles as EGFR tyrosine kinase inhibitors from the U.S. National Cancer Institute database by in silico screening and bioactivity evaluation. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2022, 58, 128524.	2.2	2
164	Global Research Trends in Tyrosine Kinase Inhibitors: Coword and Visualization Study. <i>JMIR Medical Informatics</i> , 2022, 10, e34548.	2.6	1
165	Heterogeneity among tumors with acquired resistance to EGFR tyrosine kinase inhibitors harboring <i>EGFR</i> T790M mutation in nonâ€small cell lung cancer cells. <i>Cancer Medicine</i> , 2022, 11, 944-955.	2.8	5
166	Treatment-driven tumour heterogeneity and drug resistance: Lessons from solid tumours. <i>Cancer Treatment Reviews</i> , 2022, 104, 102340.	7.7	21

#	ARTICLE	IF	CITATIONS
167	Biomarker subset analysis of a phase IIIb, open-label study of afatinib in EGFR tyrosine kinase inhibitor-naïve patients with <i>EGFR</i> ^{m+} non-small-cell lung cancer. <i>Future Oncology</i> , 2022, 18, 1485-1497.	2.4	0
168	Efficacy of Prophylactic Traditional Chinese Medicine on Skin Toxicity of Afatinib in <i>EGFR</i> Mutation-Positive Advanced Lung Adenocarcinoma: A Single-Center, Prospective, Double-Blinded, Randomized-Controlled Pilot Trial. <i>Integrative Cancer Therapies</i> , 2022, 21, 153473542210866.	2.0	4
169	Integration of liquid biopsy and pharmacogenomics for precision therapy of EGFR mutant and resistant lung cancers. <i>Molecular Cancer</i> , 2022, 21, 61.	19.2	6
170	Insights into the design of inhibitors of the EGFR family with anticancer activity overcoming resistance: A case of optimizing thieno[2,3-d]pyrimidine-based EGFR inhibitors. <i>Journal of Molecular Structure</i> , 2022, 1259, 132724.	3.6	3
171	Membrane Repairing Capability of Non-Small Cell Lung Cancer Cells Is Regulated by Drug Resistance and Epithelial-Mesenchymal-Transition. <i>Membranes</i> , 2022, 12, 428.	3.0	1
178	A randomized phase ^{II} study of docetaxel or pemetrexed with or without the continuation of gefitinib after disease progression in elderly patients with non-small cell lung cancer harboring <i>EGFR</i> mutations (^{JMTO} LC12-01). <i>Thoracic Cancer</i> , 2022, 13, 1827-1836.	1.9	2
179	Optimizing Patient Outcomes Through Sequential EGFR TKI Treatment in Asian Patients With <i>EGFR</i> Mutation-Positive NSCLC. <i>Clinical Medicine Insights: Oncology</i> , 2022, 16, 117955492211032.	1.3	2
180	Development and externally validate MRI-based nomogram to assess EGFR and T790M mutations in patients with metastatic lung adenocarcinoma. <i>European Radiology</i> , 2022, 32, 6739-6751.	4.5	9
181	Extracellular Vesicles from <i>EGFR</i> T790M/L858R-mutant Non-small Cell Lung Cancer Promote Cancer Progression. <i>Anticancer Research</i> , 2022, 42, 3835-3844.	1.1	3
182	Association between EGFR gene mutant protein expression and T790M mutation after first-generation EGFR-TKI treatment resistance: a retrospective, single-arm clinical study. <i>Annals of Translational Medicine</i> , 2022, 10, 935-935.	1.7	1
183	Drug resistance mechanisms and progress in the treatment of EGFR-mutated lung adenocarcinoma (Review). <i>Oncology Letters</i> , 2022, 24, .	1.8	16
184	Liquid Biopsy: A Multi-Parametric Analysis of Mutation Status, Circulating Tumor Cells and Inflammatory Markers in EGFR-Mutated NSCLC. <i>Diagnostics</i> , 2022, 12, 2360.	2.6	0
185	Engaging innate immunity for targeting the epidermal growth factor receptor: Therapeutic options leveraging innate immunity versus adaptive immunity versus inhibition of signaling. <i>Frontiers in Oncology</i> , 0, 12, .	2.8	3
186	New Targeted Therapy for Non-Small Cell Lung Cancer. <i>Tuberculosis and Respiratory Diseases</i> , 2023, 86, 1-13.	1.8	3
187	Afatinib and Dacomitinib Efficacy, Safety, Progression Patterns, and Resistance Mechanisms in Patients with Non-Small Cell Lung Cancer Carrying Uncommon EGFR Mutations: A Comparative Cohort Study in China (AFANDA Study). <i>Cancers</i> , 2022, 14, 5307.	3.7	6
188	Absence of copy number gain of <i>EGFR</i> : A possible predictive marker of long-term response to afatinib. <i>Cancer Science</i> , 2023, 114, 1045-1055.	3.9	5
189	Multiple mutations in the EGFR gene in lung cancer is rare but should not be forgettable. <i>Translational Lung Cancer Research</i> , 2022, 11, 2167-2169.	2.8	0
190	Therapeutic strategies for EGFR-mutated non-small cell lung cancer patients with osimertinib resistance. <i>Journal of Hematology and Oncology</i> , 2022, 15, .	17.0	46

#	ARTICLE	IF	CITATIONS
191	A real-world study of second or later-line osimertinib in patients with EGFR T790M-positive NSCLC: the final ASTRIS data. <i>Future Oncology</i> , 2023, 19, 61-75.	2.4	1
192	Treatment Strategies for Non-Small Cell Lung Cancer with Common EGFR Mutations: A Review of the History of EGFR TKIs Approval and Emerging Data. <i>Cancers</i> , 2023, 15, 629.	3.7	7
193	The Usefulness of Nanotechnology in Improving the Prognosis of Lung Cancer. <i>Biomedicines</i> , 2023, 11, 705.	3.2	1
194	Candidate mechanisms of acquired resistance to first-line osimertinib in EGFR-mutated advanced non-small cell lung cancer. <i>Nature Communications</i> , 2023, 14, .	12.8	38
195	Analysis of acquired resistance mechanisms to osimertinib in patients with EGFR-mutated advanced non-small cell lung cancer from the AURA3 trial. <i>Nature Communications</i> , 2023, 14, .	12.8	24
196	Monitoring of T790M in plasma ctDNA of advanced EGFR-mutant NSCLC patients on first- or second-generation tyrosine kinase inhibitors. <i>BMC Cancer</i> , 2023, 23, .	2.6	5
197	CT Radiomics Predict EGFR-T790M Resistance Mutation in Advanced Non-Small Cell Lung Cancer Patients After Progression on First-line EGFR-TKI. <i>Academic Radiology</i> , 2023, 30, 2574-2587.	2.5	3
198	EGFR-TKIs plus stereotactic body radiation therapy (SBRT) for stage IV Non-small cell lung cancer (NSCLC): A prospective, multicenter, randomized, controlled phase II study. <i>Radiotherapy and Oncology</i> , 2023, 184, 109681.	0.6	4
200	Ramucirumab plus erlotinib versus placebo plus erlotinib in previously untreated EGFR-mutated metastatic non-small-cell lung cancer (RELAY): exploratory analysis of next-generation sequencing results. <i>ESMO Open</i> , 2023, 8, 101580.	4.5	1
201	Editorial for “Brain Tumor Interface-Based MRI Radiomics Models to Determine EGFR Mutation, Response to EGFR-TKI and T790M Resistance Mutation in Non-Small Cell Lung Carcinoma Brain Metastasis” <i>Journal of Magnetic Resonance Imaging</i> , 0, , .	3.4	0
202	EGFR Inhibition Overcomes Resistance to FGFR4 Inhibition and Potentiates FGFR4 Inhibitor Therapy in Hepatocellular Carcinoma. <i>Molecular Cancer Therapeutics</i> , 2023, 22, 1479-1492.	4.1	0
203	Improving the efficacy of anti-EGFR drugs in GBM: Where we are going?. <i>Biochimica Et Biophysica Acta: Reviews on Cancer</i> , 2023, 1878, 188996.	7.4	1
204	Therapeutic role of EGFR - Tyrosine kinase inhibitors in non-small cell lung cancer with leptomeningeal metastasis. <i>Translational Oncology</i> , 2024, 39, 101832.	3.7	1
205	The role of anti-EGFR therapies in EGFR-TKI-resistant advanced non-small cell lung cancer. <i>Cancer Treatment Reviews</i> , 2024, 122, 102664.	7.7	2
206	Computer-Assisted Drug Discovery of a Novel Theobromine Derivative as an EGFR Protein-Targeted Apoptosis Inducer. <i>Evolutionary Bioinformatics</i> , 2023, 19, .	1.2	0
207	miR-204 suppresses cancer stemness and enhances osimertinib sensitivity in non-small cell lung cancer by targeting CD44. <i>Molecular Therapy - Nucleic Acids</i> , 2024, 35, 102091.	5.1	0
208	Next-generation sequencing reveals genetic heterogeneity and resistance mechanisms in patients with EGFR-mutated non-small cell lung cancer treated with afatinib. <i>ERJ Open Research</i> , 2024, 10, 00676-2023.	2.6	0
209	Drug-resistant EGFR mutations promote lung cancer by stabilizing interfaces in ligand-free kinase-active EGFR oligomers. <i>Nature Communications</i> , 2024, 15, .	12.8	0